Description
Palbociclib is a kinase inhibitor indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
Dosage:Palbociclib capsules come in the standard strength of 125mg, 100 mg, and 75 mg to administer orally via the mouth. Healthcare professionals recommend administering Palbociclib dosage, a 125 mg capsule taken orally once daily for 21 consecutive days followed by 7 days of treatment to comprise a complete cycle of 28 days. IBRANCE should be taken with food.
Side Effects:The common side-effects of Palbociclib are:
- neutropenia
- infections
- leukopenia
- fatigue
- nausea
- stomatitis
- anemia
- alopecia
- diarrhea
- thrombocytopenia
- rash
- vomiting
Neutropenia was the most frequently reported adverse reaction in patients administered the medicine Palbociclib. One should monitor complete blood counts prior to starting IBRANCE therapy and at the beginning of each cycle, as well as on Day 15 of the first 2 cycles, and as clinically indicated.
Based on findings from animal studies and its mechanism of action, Palbociclib can cause fetal harm when administered to a pregnant woman. Healthcare professionals advise pregnant women of the potential risk to a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Palbociclib and for at least 3 weeks after the last dose.
Males with female partners who can become pregnant should use effective birth control during treatment with IBRANCE for at least 3 months after the last dose of Palbociclib.
Breastfeeding women are advised not to feed if the female is being treated or treated for 3 weeks after the last dose of Palbociclib.
